Oppenheimer Maintains Outperform on Evolent Health, Raises Price Target to $7

Benzinga · 3d ago
Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and raises the price target from $6 to $7.